ACP
TXMD icon

Acuta Capital Partners’s TherapeuticsMD TXMD Stock Holding History

Acuta Capital Partners’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-378
Closed -$114K – 60
2015
Q1 		$114K Buy
+378
New +$92.3K 0.1% 51

Other funds holding TXMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Acuta Capital Partners's TXMD Position: Q2 2015 in Review

Acuta Capital Partners sold out of TherapeuticsMD (TXMD) in Q2 2015, closing a stake of 378 shares — an estimated $114K sold.

Acuta Capital Partners first reported a position in TXMD in Q1 2015 and held it in 1 quarter. The position peaked at $114K in Q1 2015. 115 funds tracked by Wall St. Rank hold TXMD as of Q2 2015.

  • Acuta Capital Partners reported no remaining TherapeuticsMD position as of Q2 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 378 TherapeuticsMD shares in Q2 2015, an estimated $114K.
  • Acuta Capital Partners first reported a position in TherapeuticsMD in Q1 2015 and held it in 1 quarter.
  • Acuta Capital Partners's TherapeuticsMD position peaked at $114K in Q1 2015.
  • 115 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2015.

Based on Acuta Capital Partners's 13F filing for Q2 2015, filed 14 Aug 2015.